Concord Wealth Partners’s Zomedica Corp. ZOM Stock Holding History

Concord Wealth Partners’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-600	Closed	-$1K	–	1127
2021 Q1	$1K	Buy	+600	New	+$980	﹤0.01%	989

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

KFS

Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return

Concord Wealth Partners's ZOM Position: Q2 2021 in Review

Concord Wealth Partners sold out of Zomedica Corp. (ZOM) in Q2 2021, closing a stake of 600 shares — an estimated $1K sold.

Concord Wealth Partners first reported a position in ZOM in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 106 funds tracked by Wall St. Rank hold ZOM as of Q2 2021.

Concord Wealth Partners reported no remaining Zomedica Corp. position as of Q2 2021 after selling out during the quarter.
Concord Wealth Partners sold 600 Zomedica Corp. shares in Q2 2021, an estimated $1K.
Concord Wealth Partners first reported a position in Zomedica Corp. in Q1 2021 and held it in 1 quarter.
Concord Wealth Partners's Zomedica Corp. position peaked at $1K in Q1 2021.
106 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2021.

Based on Concord Wealth Partners's 13F filing for Q2 2021, filed 29 Jul 2021.